Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00039000 | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma | PHASE3 | COMPLETED | 350 | — | — | Mar 1, 2002 | Dec 1, 2005 | Sep 7, 2012 | 77 | United States, Australia +7 |
| Name | Type | Description |
|---|---|---|
| HSPPC-96 or Oncophage | DRUG | - |
Eligibility Assessment: (The following assessments must be obtained within three weeks prior to randomization into the study) * Medical history and physical examination (including EGOG score, evidence of immunosuppression); * CT/MRI of the chest, abdomen and pelvis; * Clinical examination; * CT/MR...